Stock 690 UNI-BIO SCIENCE GROUP LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Uni-Bio Science Group Limited

Equities

690

KYG9198H1406

Pharmaceuticals

Market Closed - Hong Kong S.E.
Other stock markets
 09:08:20 14/05/2024 BST 		5-day change 1st Jan Change
0.077 HKD -2.53% Intraday chart for Uni-Bio Science Group Limited -3.75% +6.94%
03-27 Uni-Bio Science Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
02-14 Uni-Bio Science's Profit to Climb in 2023 MT

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 550 1,006 735 533.4 458.3 452.1
Enterprise Value (EV) 1 524.7 920.4 661.4 448.7 372.4 366.5
P/E ratio -3.97 x 402 x -10.3 x -27.1 x 11.9 x 6.49 x
Yield - - - - - -
Capitalization / Revenue 4.07 x 4.81 x 3.52 x 1.51 x 1.04 x 0.93 x
EV / Revenue 3.88 x 4.39 x 3.17 x 1.27 x 0.85 x 0.76 x
EV / EBITDA -5 x -15.4 x -36.4 x 41.2 x 6.26 x 3.96 x
EV / FCF -10.2 x -22.3 x -122 x 12.9 x 14.4 x 15.4 x
FCF Yield -9.84% -4.49% -0.82% 7.76% 6.93% 6.51%
Price to Book 2.73 x 4.17 x 3.88 x 3.06 x 2.35 x 1.76 x
Nbr of stocks (in thousands) 6,179,968 6,410,768 6,391,008 6,349,768 6,364,768 6,278,768
Reference price 2 0.0890 0.1570 0.1150 0.0840 0.0720 0.0720
Announcement Date 12/04/19 27/04/20 26/04/21 07/04/22 20/04/23 23/04/24
1HKD in Million2HKD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 135.3 209.4 208.8 353.4 440.3 484.7
EBITDA 1 -105 -59.64 -18.19 10.88 59.53 92.55
EBIT 1 -125.9 -78.26 -36.95 -4.833 47.24 80.88
Operating Margin -93.09% -37.36% -17.7% -1.37% 10.73% 16.69%
Earnings before Tax (EBT) 1 -138.4 5.14 -70.94 -20.01 43.29 75.9
Net income 1 -138.6 2.459 -71.32 -19.59 38.51 70.88
Net margin -102.45% 1.17% -34.16% -5.54% 8.75% 14.62%
EPS 2 -0.0224 0.000391 -0.0111 -0.003100 0.006054 0.0111
Free Cash Flow 1 -51.63 -41.34 -5.407 34.81 25.8 23.86
FCF margin -38.17% -19.74% -2.59% 9.85% 5.86% 4.92%
FCF Conversion (EBITDA) - - - 319.97% 43.34% 25.78%
FCF Conversion (Net income) - - - - 67% 33.67%
Dividend per Share - - - - - -
Announcement Date 12/04/19 27/04/20 26/04/21 07/04/22 20/04/23 23/04/24
1HKD in Million2HKD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 25.3 86.1 73.5 84.7 85.8 85.6
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -51.6 -41.3 -5.41 34.8 25.8 23.9
ROE (net income / shareholders' equity) -50.9% 1.11% -33.1% -10.8% 20.9% 31.4%
ROA (Net income/ Total Assets) -24.9% -18.2% -8.41% -1.16% 10.5% 14.4%
Assets 1 557 -13.55 848 1,687 365.3 492.4
Book Value Per Share 2 0.0300 0.0400 0.0300 0.0300 0.0300 0.0400
Cash Flow per Share 2 0.0100 0.0100 0 0.0100 0.0200 0.0200
Capex 1 1.65 8.1 3.44 8.43 28.4 59.7
Capex / Sales 1.22% 3.87% 1.65% 2.39% 6.46% 12.32%
Announcement Date 12/04/19 27/04/20 26/04/21 07/04/22 20/04/23 23/04/24
1HKD in Million2HKD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
UNI-BIO SCIENCE GROUP LIMITED Stock Uni-Bio Science Group Limited
+6.94% 62.33M
CSL LIMITED Stock CSL Limited
-2.47% 89.37B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+2.76% 40.65B
BIOGEN INC. Stock Biogen Inc.
-12.32% 32.81B
UCB Stock UCB
+52.41% 25B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-17.39% 15.29B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-42.45% 11.61B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-10.48% 11.49B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+6.14% 8.98B
INNOVENT BIOLOGICS, INC. Stock Innovent Biologics, Inc.
-7.72% 8.23B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. 690 Stock
  4. Financials Uni-Bio Science Group Limited